AnalystBook Research · Company Intelligence

Enveric Biosciences, Inc.

ENVBNasdaq

Built from Enveric Biosciences, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Net income increased 8.4% to ($8.8M), while Operating cash flow decreased 5.4% to ($8.1M).

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue N/AWatch
  • Profitability — Net income ($8.8M)Watch
  • Cash generation — Free cash flow N/ANote
  • Accounting — No applicable forensic screenNote
  • Insiders — 0 buys; 0 sells in 365 daysNote
  • Capital — Comparable payout data unavailableNote

Business

Enveric Biosciences, Inc.: On December 30, 2020, we completed a tender offer to purchase all of the outstanding common shares of Jay Pharma Inc., a Canada corporation, for shares of Company common stock or certain preferred stock, and changed our name to "Enveric Biosciences, Inc." On May 24, 2021, we entered into an Amalgamation Agreement (the "Amalgamation Agreement") with 1306432 B.C.

Latest filings

  • 10-Q · Quarterly report2026-08-14
  • 8-K · Company announcement2026-08-14
  • 8-K · Company announcement2026-06-09
  • 8-K · Company announcement2026-06-09
  • 8-K · Company announcement2026-05-29
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Enveric Biosciences, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full ENVB record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.